George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
Genf is already conducting in-vivo evaluations of its leading centenarian sirt6 gene therapy in four different nash mice models in conjunction with four leading partners in the field,
This to look forward to as the data was collected at the end of 2023. So near term results should be out in the relatively short term. All imo, of course,
Marmie
I agree although the £100k is spread over a 12 month period
Marmie
Thanks for the reply,
Marmie
Would you let us know how you know this please?
Thanks
This is not on the AIM market, by the way.
Marmie
To state the obvious, this price is ridiculous. Bought more today and will continue to hold and add,
Marmie
10-14 days to really get going but it’s an indication of where this should be going,
Marmie
Not sold a single share and bought more today. Just for the record. Drop is unjustified, and I have feeling there is someone buying and building up quite a holding. Won’t be selling any, even if it drops to all time lows.
Marmie
Sold out on results at a loss. Thankfully didn’t put much in but still a shame. They will now delist I think.
Marmie
Still holding and still think this is undervalued. If it plays out this should have a mkt cap of £10M or 7 times the price we have atm
M
Current market cap of £1.5M and on the cusp of being profitable. Should be £5M if so and with a good set of results may be even higher? I’m in, for the record.
Marmie